{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "OTLY",
  "name": "Oatly Group AB",
  "url": "https://orbyd.app/dossiers/OTLY/",
  "json_url": "https://orbyd.app/dossiers/OTLY.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Oatly doubled its FY2026 constant-currency revenue growth guide to 8–10% from 3–5% on 2026-07-22 and printed positive adjusted EBITDA (+$0.4M). The re-rating leg is roughly two weeks old, RSI is 71, and no company catalyst is scheduled inside 30 days to refresh it — against $517.8M of borrowings vs $44.6M cash.",
  "invalidation_trigger": "A weekly close below $11.00 cedes the entire advance that followed the 2026-07-22 guidance raise; secondarily, a Q3 2026 print (~2026-10-28, est.) that walks FY constant-currency growth back toward the old 3–5% band or narrows adjusted EBITDA below the $25M low end.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "consumer-discretionary-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Foreign private issuer: reports on Form 6-K and 20-F, not 10-Q/10-K.",
    "Reports in USD while the largest growth region is European — reported and constant-currency growth diverge every quarter.",
    "9.25% Convertible Senior PIK Notes due 2028-09-14 accrete interest rather than pay cash, so principal compounds absent repurchase.",
    "Capital stack is multi-currency: SEK 1,700M Nordic bonds and a SEK 750M super senior RCF (Sept 2025) alongside USD convertibles.",
    "Sell-side coverage is thin — Barclays Overweight, JPMorgan and Morgan Stanley at hold as of late July 2026."
  ],
  "body_markdown": "## Current Thesis\n\nThe leg being bought is an operating-inflection story on a heavily levered balance sheet. On 2026-07-22 Oatly reported Q2 net revenue of $240.1M, +15.2% reported and +12.7% in constant currency, against a $218.961M consensus (Benzinga), and lifted FY2026 constant-currency revenue growth guidance to 8–10% from 3–5%. Adjusted EBITDA came in at +$0.4M versus -$3.6M a year earlier and gross margin was 33.9%, up 140bps. Barclays kept Overweight and moved its target to $14 on 2026-07-23, two days after cutting it to $12 on 2026-07-21.\n\nWhat that does not fix is the capital structure: $44.6M of cash against $517.8M of total borrowings at 2026-06-30, with management pointing to the low end of the $25–35M FY adjusted-EBITDA range. The equity is a call option on the growth guide holding. As of the 2026-08-07 close of $13.72, RSI(14) sits at 71.0, the three-month return is +31.8%, and the shares are still 26.0% under the $18.54 52-week high.\n\n**Life-cycle: ACCELERATING.** Dated to the 2026-07-22 print and the 2026-07-23 Barclays revision — new numbers, a guide that doubled, fresh momentum-screen coverage. It is not MATURING because the re-rating has not reclaimed the prior 52-week range, and not SATURATED because sell-side participation is thin (JPMorgan and Morgan Stanley both at hold in late July 2026).\n\n## Bull Case\n\n- FY2026 constant-currency revenue growth guidance raised to **8–10% from 3–5%** on 2026-07-22 — a doubling of the growth assumption inside one quarter.\n- Q2 2026 revenue $240.095M vs $218.961M consensus; EPS -$0.99 vs -$1.06 consensus (Benzinga, 2026-07-22). Six-month revenue $468.4M.\n- Adjusted EBITDA crossed positive at **+$0.4M** (vs -$3.6M in Q2 2025) with gross margin at **33.9%, +140bps**. Net loss narrowed to $31.3M from $55.9M.\n- Regional breadth: Europe & International +21.0% reported / +18.0% constant currency; Greater China +11.6% / +5.6% cc; North America +5.9% with a second consecutive quarter of positive volume growth (Q2 2026 release).\n- Capital intensity is low relative to the growth rate: H1 2026 capex $10.7M.\n- Barclays Overweight, PT $14 (2026-07-23); MarketBeat-tracked average target $14.64 — both marks sit above the 2026-08-07 close of $13.72.\n\n## Bear Case\n\n- **Leverage dominates the equity.** $517.8M total borrowings vs $44.6M cash at 2026-06-30. The 9.25% Convertible Senior PIK Notes due **2028-09-14** accrete interest rather than pay it in cash, so principal compounds absent repurchase. The September 2025 refinancing (SEK 1,700M Nordic bonds, SEK 750M super senior RCF, prepayment of the $130M Term Loan B) reshuffled the stack without taking leverage to a level that $25–35M of adjusted EBITDA covers comfortably.\n- The dollar guide raise — from $866.725M–$883.555M to $908.799M–$925.629M — landed against a $917.899M consensus (Benzinga, 2026-07-22). The midpoint closed the gap to the Street rather than clearing it.\n- **FX flattered the quarter.** Reported growth 15.2% vs 12.7% constant currency is roughly 250bps of currency help. Oatly reports in USD while its largest growth region is European.\n- Management guided adjusted EBITDA toward the **low end** of $25–35M on the 2026-07-22 call, citing cost pressure and growth spend.\n- Still a loss-maker: -$31.3M net in the quarter. JPMorgan and Morgan Stanley both at hold ratings, late July 2026.\n- Shares remain -26.0% from the $18.54 52-week high (2026-08-07 basis), so the guidance raise has recovered part of a prior de-rating rather than establishing new highs.\n\n## Setup & Price Structure\n\n- Last completed daily close **$13.72** (2026-08-07). 52-week high **$18.54**. Three-month return **+31.8%**. **RSI(14) 71.0** — the overbought band.\n- The move is anchored to a single dated event. The advance to $13.72 is therefore concentrated in the weeks following 2026-07-22, consistent with a 71 RSI reading.\n- Spot sits under the $14.64 average target and under Barclays' $14, so the published marks leave little headroom absent estimate revisions.\n\n**Crowding and positioning observables (stated, not judged):**\n\n- On 2026-07-24, two days after the print, Benzinga listed OTLY in \"Top 3 Defensive Stocks That May Collapse This Quarter\" — an RSI-based overbought screen. Momentum-screen coverage clustered within 48 hours of the catalyst.\n- No scheduled company earnings event inside the next 30 days to reprice the guide.\n- Barclays cut its target to $12 on 2026-07-21 and raised it to $14 on 2026-07-23 — a two-day round trip set to the print.\n- Extension without recovery: price is 26% below the 52-week high while RSI reads 71, so the overbought condition has arrived inside a downtrend repair rather than at new highs.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-08 to 2026-09-07: no confirmed company-scheduled event.** Nothing on the public IR calendar as of 2026-08-08. The window is empty and the guidance raise has to carry the tape unaided.\n- **~2026-10-28 (est.) — Q3 2026 results.** Basis for the estimate: Q3 2025 was reported 2025-10-29 and Q3 2024 on 2024-11-07. Not confirmed by the company as of 2026-08-08. This is the first hard test of the 8–10% constant-currency guide and of whether adjusted EBITDA tracks the low or high end of $25–35M.\n- Interim disclosure: Form 6-K filings are ad hoc for a foreign private issuer — there is no quarterly 10-Q cadence to anchor to.\n\n## What Would Change Our Mind\n\nThe load-bearing number is the FY constant-currency growth guide. If the Q3 print walks 8–10% back toward the old 3–5% band, or narrows adjusted EBITDA below the $25M low end already flagged on the 2026-07-22 call, the reason the multiple moved on 2026-07-22 is gone and the leverage is what remains.\n\nSecond, the currency. Q2 reported growth ran roughly 250bps above constant currency. If Q3 reported growth prints below constant-currency growth, the $908.799M–$925.629M dollar guide is at risk with no operational deterioration required.\n\nThird, the capital structure. An equity issuance, ATM programme or dilutive refinancing announced into this strength would say management treats $13.72 as a funding level rather than a re-rating.\n\nOn price, a **weekly close below $11.00** would cede the full advance that followed the 2026-07-22 guidance raise and put the shares back inside the pre-print range. A shift of the theme to SATURATED — broad retail coverage without incremental estimate revisions — is the softer secondary condition.\n\nWhat would extend the leg instead: adjusted EBITDA tracking toward $35M rather than $25M, North America volume growth holding for a third consecutive quarter, or a refinancing that removes the 9.25% PIK coupon.\n\n## Correlation Notes\n\n- **FX is a direct P&L input.** EUR/USD and SEK/USD drive the reported-versus-constant-currency spread; Europe & International grew +21.0% reported against +18.0% cc in Q2 2026.\n- **Credit matters more than staples beta.** With $517.8M of borrowings against $44.6M cash, the shares behave closer to a leveraged-credit proxy than to a packaged-food comp. SEK-denominated Nordic bond spreads and the 2028 convertible are the relevant read-across.\n- **Greater China exposure** ties a segment to tariff and geopolitical headlines; the Q2 2026 call flagged geopolitical dynamics alongside the +5.6% cc growth there.\n- **Plant-based / alt-dairy complex:** category scanner data and competitor retail pricing move the cohort together, though Oatly is repositioning as a broader beverage business rather than a dairy-alternative pure play.\n- **Small-cap consumer momentum cohort:** with RSI at 71 and the advance concentrated into a few weeks, the shares carry exposure to momentum-factor unwinds independent of company news.",
  "first_seen": "2026-08-04",
  "last_analyzed": "2026-08-09T08:10:08+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}